Association of a single-nucleotide polymorphism from chromosome 17q12 with the aggressiveness of prostate cancer in a Hispanic population

  • Pablo A. Rojas
  • Verónica Torres-Estay
  • Javier Cerda-Infante
  • Viviana P. Montecinos
  • Javier Domínguez
  • José Arenas
  • Alejandro S. Godoy
  • Ignacio F. San FranciscoEmail author
Original Article - Cancer Research



To study the association between the polymorphisms, rs1859962 and rs4430796, from the chromosomes 17q24 and 17q12, respectively, with the risk of prostate cancer (PCa) and its clinical characteristics in a Hispanic (Chilean) population.


This study included 33 controls and 167 patients diagnosed with PCa. The polymorphisms, rs1859962 and rs4430796, were analyzed on blood specimens using quantitative PCR. The genetic analysis of the qPCR data was performed using the SNPStats program. A comparison between the clinical characteristics of the prostate cancers from the patients and the presence of the different polymorphism genotypes detected in blood specimens obtained from these patients was performed using the IBM SPSS v20.0 software.


We observed no association of the SNPs and the risk of developing PCa (OR 0.84, 95 % CI 0.30–2.38, p = 1.0 to rs1859962 and OR 1.94, 95 % CI 0.57–6.52, p = 0.28 to rs4430796), both sporadic and hereditary. However, patients carrying the genotype G/G from the polymorphism rs4430796 had significantly higher PSA levels than patients carrying the other genotypes (15.05 ng/ml to G/G, 10 and 8.11 ng/ml to genotypes A/G y A/A, respectively, p = 0.01). Furthermore, patients with the genotype G/G of rs4430796 had higher tumor volume than other genotypes (9.45 cc to G/G and 5.22 cc to A/G + A/A, p = 0.04).


The polymorphism rs4430796 of the chromosome 17q12 appears to be a biomarker for cancer aggressiveness, increased PSA and tumor volume of PCa.


17q12 17q24 rs4430796 Prostate cancer  Single-nucleotide polymorphism 



The authors thank the patients who participated in the study selflessly. The study was supported by FONDECYT No. 11110334.

Conflict of interest

The authors declare that they have no competing interests.


  1. Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC (1993) Hereditary prostate cancer: epidemiologic and clinical features. J Urol 150:797–802PubMedGoogle Scholar
  2. Chan JY, Li H, Singh O, Mahajan A, Ramasamy S, Subramaniyan K, Kanesvaran R, Sim HG, Chong TW, Teo YY et al (2013) 8q24 and 17q prostate cancer susceptibility loci in a multiethnic Asian cohort. Urol Oncol 31:1553–1560CrossRefPubMedGoogle Scholar
  3. Chang BL, Isaacs SD, Wiley KE, Gillanders EM, Zheng SL (2005) Genome-wide screen for prostate cancer susceptibility genes in men with clinically significant disease. Prostate 11:356–361CrossRefGoogle Scholar
  4. Conlon EM, Goode EL, Gibbs M, Stanford JL, Badzioch M, Janer M, Kolb S, Hood L, Ostrander EA, Jarvik GP et al (2003) Oligogenic segregation analysis of hereditary prostate cancer pedigrees: evidence for multiple loci affecting age at onset. Int J Cancer 105:630–635CrossRefPubMedGoogle Scholar
  5. Cui J, Staples MP, Hopper JL, English DR, McCredie MR, Giles GC (2001) Segregation analyses of 1,476 population-based Australian families affected by prostate cancer. Am J Hum Genet 68:1207–1218CrossRefPubMedPubMedCentralGoogle Scholar
  6. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI (2003) Pathological and molecular aspects of prostate cancer. Lancet 361:955–964CrossRefPubMedGoogle Scholar
  7. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J et al (2008) Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 40:316–321CrossRefPubMedGoogle Scholar
  8. Gong G, Oakley-Girvan I, Wu AH, Kolonel LN, John EM, West DW, Felberg A, Gallagher RP, Whittemore AS (2002) Segregation analysis of prostate cancer in 1,719 white, african-american and asian-american families in the United States and Canada. Cancer Causes Control 13:471–482CrossRefPubMedGoogle Scholar
  9. Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A, Rafnar T, Gudbjartsson D, Agnarsson BA, Baker A et al (2007) Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 39:977–983CrossRefPubMedGoogle Scholar
  10. Hu YL, Zhong D, Pang F, Ning QY, Zhang YY, Hu YL, Li G, Wu JZ, Mo ZN (2013) HNF1b is involved in prostate cancer risk via modulating androgenic hormone effects and coordination with other genes. Genet Mol Res 12:1327–1335CrossRefPubMedGoogle Scholar
  11. Iniesta R, Guino E, Moreno V (2005) Statistical analysis of genetic polymorphisms in epidemiological studies. Gac Sanit 19:333–341CrossRefPubMedGoogle Scholar
  12. Levin AM, Machiela MJ, Zuhlke KA, Ray AM, Cooney KA, Douglas JA (2008) Chromosome 17q12 variants contribute to risk of early-onset prostate cancer. Cancer Res 68:6492–6495CrossRefPubMedPubMedCentralGoogle Scholar
  13. Liu M, Suzuki M, Arai T, Sawabe M, Enomoto Y, Nishimatsu H, Kume H, Homma Y, Kitamura T (2011) A replication study examining three common single-nucleotide polymorphisms and the risk of prostate cancer in a Japanese population. Prostate 71:1023–1032CrossRefPubMedGoogle Scholar
  14. Penney KL, Salinas CA, Pomerantz M, Schumacher FR, Beckwith CA, Lee GS, Oh WK, Sartor O, Ostrander EA, Kurth T et al (2009) Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res 15:3223–3230CrossRefPubMedPubMedCentralGoogle Scholar
  15. San Francisco IF, Rojas PA, Torres-Estay V, Smalley S, Cerda-Infante J, Montecinos VP, Hurtado C, Godoy AS (2014) Association of RNASEL and 8q24 variants with the presence and aggressiveness of hereditary and sporadic prostate cancer in a Hispanic population. J Cell Mol Med 18:125–133CrossRefPubMedGoogle Scholar
  16. Shen H, Powers N, Saini N, Comstock CE, Sharma A (2008) The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. Cancer Res 11:10154–10162CrossRefGoogle Scholar
  17. Sole X, Guino E, Valls J, Iniesta R, Moreno V (2006) SNPStats: a web tool for the analysis of association studies. Bioinformatics 22:1928–1929CrossRefPubMedGoogle Scholar
  18. Sun J, Purcell L, Gao Z, Isaacs SD, Wiley KE, Hsu FC, Liu W, Duggan D, Carpten JD, Grönberg H et al (2008) Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans. Prostate 68:691–697CrossRefPubMedPubMedCentralGoogle Scholar
  19. Valeri A, Briollais L, Azzouzi R, Fournier G, Mangin P, Berthon P, Cussenot O, Demenais F (2003) Segregation analysis of prostate cancer in France: evidence for autosomal dominant inheritance and residual brotherbrother dependence. Ann Hum Genet 67:125–137CrossRefPubMedGoogle Scholar
  20. Wolf M, Mousses S, Hautaniemi S, Karhu R, Huusko P (2004) High resolution analysis of gene copy number alterations in human prostate cancer using CGH on cDNA microarrays: impact of copy number on gene expression. Neoplasia 11:240–247CrossRefGoogle Scholar
  21. Yamada H, Penney KL, Takahashi H, Katoh T, Yamano Y, Yamakado M, Kimura T, Kuruma H, Kamata Y, Egawa S et al (2009) Replication of prostate cancer risk loci in a Japanese case–control association study. J Natl Cancer Inst 101:1330–1336CrossRefPubMedGoogle Scholar
  22. Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami HO, Hsu FC, Zhu Y, Bälter K et al (2008) Cumulative association of five genetic variants with prostate cancer. N Engl J Med 358:910–919CrossRefPubMedGoogle Scholar
  23. Zhou CH, Wang JY, Cao SY, Shi XH, Zhang YG, Liu M, Wang X, Huang J, Yang YG, Wei D et al (2011) Association between single nucleotide polymorphisms on chromosome 17q and the risk of prostate cancer in a Chinese population. Chin J Cancer 30:721–730CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Pablo A. Rojas
    • 1
  • Verónica Torres-Estay
    • 2
  • Javier Cerda-Infante
    • 3
  • Viviana P. Montecinos
    • 3
  • Javier Domínguez
    • 1
  • José Arenas
    • 4
  • Alejandro S. Godoy
    • 2
    • 5
  • Ignacio F. San Francisco
    • 1
    Email author
  1. 1.Departamento de Urología, Facultad de MedicinaPontificia Universidad Católica de ChileSantiagoChile
  2. 2.Departamento de Ciencias Fisiológicas, Facultad de Ciencias BiológicasPontificia Universidad Católica de ChileSantiagoChile
  3. 3.Departamento de Hemato-Oncología, Facultad de MedicinaPontificia Universidad Católica de ChileSantiagoChile
  4. 4.Servicio de UrologíaComplejo Asistencial Hospital Doctor Sótero del RíoSantiagoChile
  5. 5.Department of UrologyRoswell Park Cancer InstituteBuffaloUSA

Personalised recommendations